Characteristics of patients with MLL-r AML in the AML-05 and TARGET cohorts
| . | AML-05 (n = 56) . | TARGET (n = 104) . | Total (N = 160) . | |||
|---|---|---|---|---|---|---|
| . | n . | % . | n . | % . | n . | % . |
| Sex | ||||||
| Male | 24 | 42.9 | 48 | 46.2 | 72 | 45.0 |
| Female | 32 | 57.1 | 56 | 53.8 | 88 | 55.0 |
| Median age (range), y | 3.0 | 0.0-15.1 | 4.2 | 0.1-18.2 | 3.9 | 0.0-18.2 |
| Median WBC (range), ×109/L | 27.4 | 1.1-459.0 | 34.0 | 1.3-610.0 | 32.6 | 1.1-610.0 |
| FAB subtype | ||||||
| M0 | 0 | 0.0 | 3 | 2.9 | 3 | 1.9 |
| M1 | 4 | 7.1 | 3 | 2.9 | 7 | 4.4 |
| M2 | 1 | 1.8 | 2 | 1.9 | 3 | 1.9 |
| M4 | 14 | 25.0 | 16 | 15.4 | 30 | 18.8 |
| M5 | 33 | 58.9 | 66 | 63.5 | 99 | 61.9 |
| M7 | 0 | 0.0 | 1 | 1.0 | 1 | 0.6 |
| RAEB-T | 1 | 1.8 | 0 | 0.0 | 1 | 0.6 |
| NOS | 0 | 0.0 | 1 | 1.0 | 1 | 0.6 |
| Unknown | 3 | 5.4 | 12 | 11.5 | 15 | 9.4 |
| Fusion partner | ||||||
| MLLT3 | 25 | 44.6 | 38 | 36.5 | 63 | 39.4 |
| MLLT10 | 11 | 19.6 | 26 | 25.0 | 37 | 23.1 |
| ELL | 10 | 17.9 | 13 | 12.5 | 23 | 14.4 |
| MLLT1 | 5 | 8.9 | 6 | 5.8 | 11 | 6.9 |
| MLLT4 | 3 | 5.4 | 9 | 8.7 | 12 | 7.5 |
| Others | 2 | 3.6 | 12 | 11.5 | 14 | 8.8 |
| . | AML-05 (n = 56) . | TARGET (n = 104) . | Total (N = 160) . | |||
|---|---|---|---|---|---|---|
| . | n . | % . | n . | % . | n . | % . |
| Sex | ||||||
| Male | 24 | 42.9 | 48 | 46.2 | 72 | 45.0 |
| Female | 32 | 57.1 | 56 | 53.8 | 88 | 55.0 |
| Median age (range), y | 3.0 | 0.0-15.1 | 4.2 | 0.1-18.2 | 3.9 | 0.0-18.2 |
| Median WBC (range), ×109/L | 27.4 | 1.1-459.0 | 34.0 | 1.3-610.0 | 32.6 | 1.1-610.0 |
| FAB subtype | ||||||
| M0 | 0 | 0.0 | 3 | 2.9 | 3 | 1.9 |
| M1 | 4 | 7.1 | 3 | 2.9 | 7 | 4.4 |
| M2 | 1 | 1.8 | 2 | 1.9 | 3 | 1.9 |
| M4 | 14 | 25.0 | 16 | 15.4 | 30 | 18.8 |
| M5 | 33 | 58.9 | 66 | 63.5 | 99 | 61.9 |
| M7 | 0 | 0.0 | 1 | 1.0 | 1 | 0.6 |
| RAEB-T | 1 | 1.8 | 0 | 0.0 | 1 | 0.6 |
| NOS | 0 | 0.0 | 1 | 1.0 | 1 | 0.6 |
| Unknown | 3 | 5.4 | 12 | 11.5 | 15 | 9.4 |
| Fusion partner | ||||||
| MLLT3 | 25 | 44.6 | 38 | 36.5 | 63 | 39.4 |
| MLLT10 | 11 | 19.6 | 26 | 25.0 | 37 | 23.1 |
| ELL | 10 | 17.9 | 13 | 12.5 | 23 | 14.4 |
| MLLT1 | 5 | 8.9 | 6 | 5.8 | 11 | 6.9 |
| MLLT4 | 3 | 5.4 | 9 | 8.7 | 12 | 7.5 |
| Others | 2 | 3.6 | 12 | 11.5 | 14 | 8.8 |
Data are number (percentage) of patients, unless otherwise stated.
NOS, not otherwise specified.